Drug intelligence / Profile preview

Byprol

Development stage: Preclinical
Lead developer: AOP Health
Administration: Oral

Overview

Byprol is an orphan drug asset that was part of the mid-to-late stage pipeline of AOP Orphan Pharmaceuticals. Elan acquired AOP Orphan Pharmaceuticals, intending to diversify its business into the orphan drug market and gain assets like Byprol for neuroblastoma.

Beyond the preview

Go deeper on Byprol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Byprol.

Explore the full profile